BERNA: A century of immunobiological innovation

Vaccine

Volumn 17, Issue SUPPL. 2, 1999, Pages

  Cryz Jr , Stanley J ^a  

^a Berna Biotech AG   (Switzerland)

Author keywords

Attenuated; Live; Vaccines; Virosomes

Indexed keywords

CHOLERA VACCINE; DIPHTHERIA VACCINE; HEPATITIS A VACCINE; IMMUNOGLOBULIN; INFLUENZA VACCINE; PLAGUE VACCINE; RABIES VACCINE; SMALLPOX VACCINE; TETANUS TOXOID; TYPHOID VACCINE;

CONFERENCE PAPER; ENTEROBACTERIACEAE; GENE TECHNOLOGY; GENE THERAPY; IMMUNIZATION; IMMUNOBIOLOGY; IMMUNOGENICITY; PRIORITY JOURNAL;

EID: 0345466579     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00228-5     Document Type: Conference Paper

References (16)

1. Germanier R., Fürer E. Immunity in experimental salmonellosis. Part II: Basis for the avirulence and protective capacity of gal E mutants of Salmonella typhimurium. Infect. Immun. 4:1977;663-673.
2. Germanier R., Fürer E. Isolation and characterization of gal E mutant Ty21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J. Infect. Dis. 131:1975;553-558.
3. Gilman R.H., Hornick R.B., Woodward W.E., DuPont H.L., Snyder M.J., Levine M.M., Libonati J.P. Evaluation of UDP-glucose-e-epimeraseless mutant of Salmonella typhi as a live oral vaccine. J. Infect. Dis. 136:1977;717-723.
4. Wahdan M.H., Serie C., Cerisier Y., Sallam S., Germanier R. A controlled field trial of live Salmonella typhi strain Ty21a oral vaccine against typhoid: three-year results. J. Infect. Dis. 145:1982;292-296.
5. Levine M.M., Ferreccio C., Black R.E., Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet. 1:1987;1049-1052.
6. Black R.E., Levine M.M., Ferreccio C., Clements M.L., Lanata C., Rooney J., Germanier R. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. Vaccine. 6:1990;81-84.
7. Ferreccio C., Levine M.M., Rodriguez H., Contreras R. Comparative efficacy of two, three, or four doses of Ty21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. J. Infect. Dis. 159:1989;766-769.
8. Simanjuntak C, Paleologo FP, Punjabi NH, Darmowigoto R, Soeprawoto, Totosudirjo H, Haryanto P, Suprijanto E, Witham ND, Hoffman SL. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet 1991;338:1055-1059.
9. Levine M.M., Ferreccio C., Cryz S.J. Jr, Ortiz E. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet. 336:1990;891-894.
10. Cryz S.J. Jr. Post-marketing experience with live oral Ty21a vaccine. Lancet. 341:1993;49-50.
11. Kaper J.B., Tacket C.O., Levine M.M. Strains as live oral cholera vaccines. Levine M.M., Woodrow G.C., Kaper J.B., Cobon G.S. New Generation Vaccines. 1997;447-457 Marcel Dekker, New York, NY.
12. Davis R., Spencer C.M. Live oral cholera vaccine. Clin. Immunother. 4:1995;235-247.
13. Glück R., Mischler R., Brantschen S., Just M., Althaus B., Cryz S.J. Jr. Immuno-potentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J. Clin. Invest. 90:1992;2491-2495.
14. Lea A.P., Balfour A. Virosomal hepatitis A vaccine (strain RG-SB). BioDrugs. 7:1997;232-248.
15. Conne P., Gauthey L., Vernet P., Althaus B., Que J.U., Finkel B., Glück R., Cryz S.J. Jr. Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine. 15:1997;1675-1679.
16. Glück R., Mischler R., Finkel B., Que J.U., Scarpa B., Cryz S.J. Jr. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet. 344:1994;160-163.